Radicle GI Health 24: A Study of Health and Wellness Products on GI Health and Related Health Outcomes

Radicle GI Health™ 24: A Randomized, Double-Blind, Placebo-Controlled, Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Gastrointestinal (GI) Health and Related Health Outcomes

A randomized, double-blind, placebo-controlled study assessing the impact of health and wellness products on GI health and related health outcomes

Study Overview

• Status: Completed
• Conditions: Abdominal Pain; Digestion; GI Disorders
• Intervention / Treatment: Dietary supplement: Radicle GI Health Placebo Control Form 1; Dietary supplement: Radicle GI Health Active Study Product 1.1 Usage; Dietary supplement: Radicle GI Health Active Study Product 2.1 Usage; Dietary supplement: Radicle GI Health Active Study Product 3.1 Usage; Dietary supplement: Radicle GI Health Placebo Control Form 2; Dietary supplement: Radicle GI Health Placebo Control Form 3; Dietary supplement: Radicle GI Health Placebo Control Form 4; Dietary supplement: Radicle GI Health Active Study Product 4.1 Usage; Dietary supplement: Radicle GI Health Placebo Control Form 5; Dietary supplement: Radicle GI Health Active Study Product 5.1 Usage; Dietary supplement: Radicle GI Health Placebo Control Form 7; Dietary supplement: Radicle GI Health Active Study Product 7.1 Usage; Dietary supplement: Radicle GI Health Active Study Product 7.2.1 Usage; Dietary supplement: Radicle GI Health Active Study Product 7.3.1 Usage; Dietary supplement: Radicle GI Health Placebo Control 7.2; Dietary supplement: Radicle GI Health Placebo Control 7.3.0; Dietary supplement: Radicle GI Health Placebo Control 7.4.0; Dietary supplement: Radicle GI Health Active Study Product 7.4.1 Usage

Detailed Description

This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States.

Eligible participants will (1) endorse a desire for improved bowel habits, less bloating/indigestion, and/or fewer stomach aches/pains (2) have the opportunity for meaningful improvement (at least 20%) in their primary health outcome, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study.

Participants that report a known cardiac dysfunction, liver or kidney disease may be excluded. Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded.

Self-reported data are collected electronically from eligible participants for 7 weeks. Participant reports of health indicators will be collected at baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.

• Study Type: Interventional
• Enrollment (Actual): 4607
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • Del Mar, California, United States, 92014
      • Radicle Science, Inc

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities. Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed
• Resides in the United States
• Endorses a desire for improved bowel habits, less bloating/indigestion, and/or fewer stomach aches/pains
• Has the opportunity for at least 20% improvement in their primary health outcome
• Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study

Exclusion Criteria:

• Report being pregnant, trying to become pregnant, or breastfeeding
• Unable to provide a valid US shipping address and mobile phone number
• Reports current enrollment in another clinical trial
• Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
• Unable to read and understand English
• Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk.
• Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients. NYHA (New York Heart Association) Class Ill or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure
• Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients. Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOls (monoamine oxidase inhibitors), or thyroid products
• Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study product
• Lack of reliable daily access to the internet

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

18

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Active Product 1.1; GI Health Product Form 1 - active product 1	Dietary supplement: Radicle GI Health Active Study Product 1.1 Usage; Participants will use their Radicle GI Health Active Study Product 1.1 as directed for a period of 6 weeks.
Placebo Comparator: Placebo Control 2; GI Health Product Form 2 - control	Dietary supplement: Radicle GI Health Placebo Control Form 2; Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
Experimental: Active Product 2.1; GI Health Product Form 2 - active product 1	Dietary supplement: Radicle GI Health Active Study Product 2.1 Usage; Participants will use their Radicle GI Health Active Study Product 2.1 as directed for a period of 6 weeks.
Placebo Comparator: Placebo Control 3; GI Health Product Form 3 - control	Dietary supplement: Radicle GI Health Placebo Control Form 3; Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
Experimental: Active Product 3.1; GI Health Product Form 3 - active product 1	Dietary supplement: Radicle GI Health Active Study Product 3.1 Usage; Participants will use their Radicle GI Health Active Study Product 3.1 as directed for a period of 6 weeks.
Placebo Comparator: Placebo Control 4; GI Health Product Form 4 - control	Dietary supplement: Radicle GI Health Placebo Control Form 4; Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
Experimental: Active Product 4.1; GI Health Product Form 4 - active product 1	Dietary supplement: Radicle GI Health Active Study Product 4.1 Usage; Participants will use their Radicle GI Health Active Study Product 4.1 as directed for a period of 6 weeks.
Placebo Comparator: Placebo Control 5; GI Health Product Form 5 - control	Dietary supplement: Radicle GI Health Placebo Control Form 5; Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.
Experimental: Active Product 5.1; GI Health Product Form 5 - active product 1	Dietary supplement: Radicle GI Health Active Study Product 5.1 Usage; Participants will use their Radicle GI Health Active Study Product 5.1 as directed for a period of 6 weeks.
Placebo Comparator: Placebo Control 1.1; GI Health Product Form 1 - control	Dietary supplement: Radicle GI Health Placebo Control Form 1; Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
Placebo Comparator: Placebo Control 7.1.0; GI Health Product Form 7.1- control	Dietary supplement: Radicle GI Health Placebo Control Form 7; Participants will use their Placebo Control Form 7 as directed for a period of 6 weeks.
Experimental: Active Product 7.1.1; GI Health Product Form 7.1 - active product 1	Dietary supplement: Radicle GI Health Active Study Product 7.1 Usage; Participants will use their Radicle GI Health Active Study Product 7.1 as directed for a period of 6 weeks.
Placebo Comparator: Placebo Control 7.2.0; GI Health Product Form 7.2 - control	Dietary supplement: Radicle GI Health Placebo Control 7.2; Participants will use their Placebo Control 7.2 as directed for a period of 6 weeks.
Experimental: Active Product 7.2.1; GI Health Product Form 7.2 - active product 1	Dietary supplement: Radicle GI Health Active Study Product 7.2.1 Usage; Participants will use their Radicle GI Health Active Study Product 7.2.1 as directed for a period of 6 weeks.
Placebo Comparator: Placebo Control 7.3.0; GI Health Product Form 7.3 - control	Dietary supplement: Radicle GI Health Placebo Control 7.3.0; Participants will use their Placebo Control 7.3 as directed for a period of 6 weeks.
Experimental: Active Product 7.3.1; GI Health Product Form 7.3 - active product 1	Dietary supplement: Radicle GI Health Active Study Product 7.3.1 Usage; Participants will use their Radicle GI Health Active Study Product 7.3.1 as directed for a period of 6 weeks.
Placebo Comparator: Placebo Control 7.4.0; GI Health Product Form 7.4 - control	Dietary supplement: Radicle GI Health Placebo Control 7.4.0; Participants will use their Placebo Control 7.4 as directed for a period of 6 weeks.
Experimental: Active Product 7.4.1; GI Health Product Form 7.4 - active product 1	Dietary supplement: Radicle GI Health Active Study Product 7.4.1 Usage; Participants will use their Radicle GI Health Active Study Product 7.4.1 as directed for a period of 6 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in GI (Gastrointestinal) Health (1)	Mean difference in Gastrointestinal Health scores as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Belly Pain 5A (scale 2-25; with higher scores corresponding to more severe abdominal pain)	6 weeks
Change in GI (Gastrointestinal) Health (2)	Mean difference in Gastrointestinal Health scores as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Gas and Bloating 13A (scale 2-60; with higher scores corresponding to more severe gas/bloating)	6 weeks
Change in GI (Gastrointestinal) Health (3)	Mean difference in GI Health scores as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Constipation 9A (scale 5-45; with higher scores corresponding to more severe constipation)	6 weeks
Change in GI (Gastrointestinal) Health (4)	Mean difference in GI Health scores as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Diarrhea 6A (scale 2-30; with higher scores corresponding to more severe diarrhea)	6 weeks
Change in GI (Gastrointestinal) Health (5)	Mean difference in GI Health scores as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Gastroesophageal Reflux 13A (scale 8-64; with higher scores corresponding to more severe reflux)	6 weeks
Change in GI (Gastrointestinal) Health (6)	Mean difference in GI Health scores as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Nausea and Vomiting 4A (scale 3-20; with higher scores corresponding to more severe nausea and vomiting)	6 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in feelings of anxiety	Mean difference in anxiety score as assessed by PROMIS Anxiety 4A (scale 4-20; with higher scores corresponding to more severe anxiety)	6 weeks
Change in mood (emotional distress-depression)	Mean difference in emotional distress score as assessed by PROMIS Emotional Distress- Depression 4A (scale 4-20; with higher scores corresponding to greater levels of emotional distress)	6 weeks
Change in GI-related Quality of Life (QOL)	Mean difference in GI-related QOL as assessed by Digestion-associated QOL Questionnaire (DGLQ) (scale 0%-100%; with higher scores corresponding to worse GI-related QOL)	6 weeks
Minimal clinically important difference (MCID) in GI Health (1)	Likelihood of experiencing minimal clinically important difference in GI Health score as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Belly Pain 5A (scale 2-25; with higher scores corresponding to more severe abdominal pain)	6 weeks
Minimal clinically important difference (MCID) in GI Health (2)	Likelihood of experiencing minimal clinically important difference in GI Health score as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Gas and Bloating 13A (scale 2-60; with higher scores corresponding to more severe gas/bloating)	6 weeks
Minimal clinically important difference (MCID) in GI Health (3)	Likelihood of experiencing minimal clinically important difference in GI Health score as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Constipation 9A (scale 5-45; with higher scores corresponding to more severe constipation)	6 weeks
Minimal clinically important difference (MCID) in GI Health (4)	Likelihood of experiencing minimal clinically important difference in GI Health score as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Diarrhea 6A (scale 2-30; with higher scores corresponding to more severe diarrhea)	6 weeks
Minimal clinically important difference (MCID) in GI Health (5)	Likelihood of experiencing minimal clinically important difference in GI Health score as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Gastroesophageal Reflux 13A (scale 8-64; with higher scores corresponding to more severe reflux)	6 weeks
Minimal clinically important difference (MCID) in GI Health (6)	Likelihood of experiencing minimal clinically important difference in GI Health score as assessed by Patient Reported Outcome Measurement System (PROMIS) Gastrointestinal Nausea and Vomiting 4A (scale 3-20; with higher scores corresponding to more severe nausea and vomiting)	6 weeks
Minimal clinically important difference (MCID) in feelings of anxiety	Likelihood of experiencing minimal clinically important difference in feelings of anxiety score as assessed by PROMIS Anxiety 4A (scale 4-20; with higher scores corresponding to more severe anxiety)	6 weeks
Minimal clinically important difference (MCID) in GI-related QOL	Likelihood of experiencing minimal clinically important difference in GI-related QOL score as assessed by Digestion-associated QOL Questionnaire (DGLQ) (scale 0%-100%; with higher scores corresponding to worse GI-related QOL)	6 weeks
Minimal clinically important difference (MCID) in mood (emotional distress-depression)	Likelihood of experiencing minimal clinically important difference in mood score as assessed by PROMIS Emotional Distress- Depression 4A (scale 4-20; with higher scores corresponding to greater levels of emotional distress)	6 weeks

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in concentration of at-home (direct-to-consumer) specimen assays either saliva, blood or stool	Mean difference in specimen assays as surrogates and/or markers for health outcomes. (Optional; among consented participants only) Potentially include saliva (IgG, cytokines, DHEA-S, Estradiol, Progesterone, Testosterone, Cortisol, Melatonin, CRP) blood (1 drop) (Cortisol, Homocysteine, Ferritin, TSH, HbA1c, Insulin, Vitamin D, DHEA-S, Testosterone, Estradiol, FSH, Total Cholesterol, HDL, LDL, Triglycerides, ApoA1, ApoB). Stool (microbial diversity). Test are optional. Unit of measure will vary based on test selected	6 weeks

Collaborators and Investigators

• Sponsor: Radicle Science
• Investigators: Principal Investigator: Emily K. Pauli, PharmD, Radicle Science Inc.

Publications and helpful links

Helpful Links

• Radicle Science, Inc

Study record dates

Study Major Dates

• Study Start (Actual): April 29, 2024
• Primary Completion (Actual): June 5, 2025
• Study Completion (Actual): June 5, 2025

Study Registration Dates

• First Submitted: March 28, 2024
• First Submitted That Met QC Criteria: April 18, 2024
• First Posted (Actual): April 19, 2024

Study Record Updates

• Last Update Posted (Estimated): October 2, 2025
• Last Update Submitted That Met QC Criteria: September 30, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Signs and Symptoms, Digestive; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Digestive System Diseases; Abdominal Pain
• Other Study ID Numbers: RADX-P-2407

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Data will not be shared with researchers outside of Radicle Collaborators on this study.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No